Your privacy is very important for us. When you visit our website, please agree to use all cookies. For more information about how we use cookies, please visit our Privacy Policy.

d1_banpc.jpg d1_banph.jpg

Pipeline

Clinical Stage Programs

Program
MOA
Indications
IND
Phase I
Phase II
Phase III
Rights
LM-302
Anti-Claudin18.2 ADC
3L+ GC/GEJ
Global available
LM-302
Anti-Claudin18.2 ADC
1L GC/GEJ
Global available
LM-302
Anti-Claudin18.2 ADC
PDAC
Global available
LM-108
Anti-CCR8 mAb
MSI-H tumors
ex-China available
LM-108
Anti-CCR8 mAb
2L GC/GEJ
ex-China available
LM-101
Anti-SIRPα mAb
Solid tumors & hematologic malignancies
Global available
LM-305
Anti-GPRC5D ADC
Multiple Myeloma
AstraZeneca (Global)
LM-24C5
CEACAM5 BsAb
CRC, GI cancer, lung cancer
Global available
LM-299
anti-PD-1 x anti-VEGF BsAb
Solid tumors
MSD (Global)
LM-168
Anti-CTLA4 (TME specific)
Solid tumors
Global available
LM-2417
Anti-NaPi2b BsAb
Lung cancer, ovarian cancer
Global available
Clinical Stage Programs
LM-302
3L+ GC/GEJ
IND
Phase I
Phase II
Phase III
MOA
Anti-Claudin18.2 ADC
Rights
Global available
LM-302
1L GC/GEJ
IND
Phase I
Phase II
Phase III
MOA
Anti-Claudin18.2 ADC
Rights
Global available
LM-302
PDAC
IND
Phase I
Phase II
Phase III
MOA
Anti-Claudin18.2 ADC
Rights
Global available
LM-108
MSI-H tumors
IND
Phase I
Phase II
Phase III
MOA
Anti-CCR8 mAb
Rights
ex-China available
LM-108
2L GC/GEJ
IND
Phase I
Phase II
Phase III
MOA
Anti-CCR8 mAb
Rights
ex-China available
LM-101
Solid tumors & hematologic malignancies
IND
Phase I
Phase II
Phase III
MOA
Anti-SIRPα mAb
Rights
Global available
LM-305
Multiple Myeloma
IND
Phase I
Phase II
Phase III
MOA
Anti-GPRC5D ADC
Rights
AstraZeneca (Global)
LM-24C5
CRC, GI cancer, lung cancer
IND
Phase I
Phase II
Phase III
MOA
CEACAM5 BsAb
Rights
Global available
LM-299
Solid tumors
IND
Phase I
Phase II
Phase III
MOA
anti-PD-1 x anti-VEGF BsAb
Rights
MSD (Global)
LM-168
Solid tumors
IND
Phase I
Phase II
Phase III
MOA
Anti-CTLA4 (TME specific)
Rights
Global available
LM-2417
Lung cancer, ovarian cancer
IND
Phase I
Phase II
Phase III
MOA
Anti-NaPi2b BsAb
Rights
Global available

Preclinical Stage Programs

Program
MOA
Indications
Discovery
PCC
IND-enabling
Rights
LM-350
anti-CDH17 ADC
CRC, PDAC, GC
Global available
LM-364
Undisclosed ADC
NSCLC, HNSCC, UC
Global available
LM-338
Undisclosed ADC
CRC, NSCLC, GC
Global available
LM-359
Undisclosed ADC
HCC
Global available
LM-319
Undisclosed ADC
TNBC, lung cancer
Global available
LM-316
Undisclosed ADC
NSCLC, OC, TNBC
Global available
LM-339
Undisclosed ADC
NSCLC, OC
Global available
LM-2199
Undisclosed BsAb
NSCLC, CRC, HNSCC, GC
Global available
Clinical Stage Programs
LM-350
CRC, PDAC, GC
Discovery
PCC
IND-enabling
MOA
anti-CDH17 ADC
Rights
Global available
LM-364
NSCLC, HNSCC, UC
Discovery
PCC
IND-enabling
MOA
Undisclosed ADC
Rights
Global available
LM-338
CRC, NSCLC, GC
Discovery
PCC
IND-enabling
MOA
Undisclosed ADC
Rights
Global available
LM-359
HCC
Discovery
PCC
IND-enabling
MOA
Undisclosed ADC
Rights
Global available
LM-319
TNBC, lung cancer
Discovery
PCC
IND-enabling
MOA
Undisclosed ADC
Rights
Global available
LM-316
NSCLC, OC, TNBC
Discovery
PCC
IND-enabling
MOA
Undisclosed ADC
Rights
Global available
LM-339
NSCLC, OC
Discovery
PCC
IND-enabling
MOA
Undisclosed ADC
Rights
Global available
LM-2199
NSCLC, CRC, HNSCC, GC
Discovery
PCC
IND-enabling
MOA
Undisclosed BsAb
Rights
Global available